Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes
Open Access
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 47 (8) , 884-889
Abstract
Carfilzomib (CFZ) is a proteasome inhibitor used for oncology indication such as treating multiple myeloma. CFZ is a potent cytotoxic agent with an IC50 in nanomolar range in various cancer cell lines and was considered as a potential payload for antibody drug conjugates (ADCs). However, the conjugated CFZ to anti-CD22 or anti-HER2 antibody totally abolishes the in vitro potency. This was a surprise since with other payload such as monomethyl auristatin E (MMAE) where a potent anti-proliferation efficacy was retained as MMAE alone or as a payload in an ADC. Further investigations were conducted using CFZ alone, CFZ with a linker and CFZ-ADC with tissue matrices including lysosomal enzymes. With CFZ linked to the ADC, cathepsin B (lysosomal enzyme) was efficient in liberating CFZ from the ADC by cleavage of valine-citrulline linker. At the same time, the liberated CFZ in the lysosome was inactivated by further metabolism by lysosomal enzymes. The metabolic profiles demonstrated that the products from epoxide and amide hydrolysis were identified from these incubations. These results suggested that the CFZ-ADC upon uptake and internalization specifically delivers CFZ payload to the lysosomes, where the CFZ was inactivated. On the other hand, CFZ by itself is not as vulnerable and could reach its target. Therefore, the lysosomal stability is an important criterion in the selection of a payload for making next generation of potent ADC therapeutics. SIGNIFICANCE STATEMENT N/AKeywords
This publication has 23 references indexed in Scilit:
- U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple MyelomaClinical Cancer Research, 2013
- From epoxomicin to carfilzomib: chemistry, biology, and medical outcomesNatural Product Reports, 2013
- Antibody‐Drug Conjugates for the Treatment of CancerChemical Biology & Drug Design, 2012
- Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphomaLeukemia, 2010
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- Antibody targeted drugs as cancer therapeuticsNature Reviews Drug Discovery, 2006
- Epoxide Hydrolases: Structure, Function, Mechanism, and Assay2005
- The proteasome: a suitable antineoplastic targetNature Reviews Cancer, 2004
- cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityBlood, 2003
- Development of potent monoclonal antibody auristatin conjugates for cancer therapyNature Biotechnology, 2003